Prognosis following transcatheter arterial embolization for 121 patients with unresectable hepatocellular carcinoma with or without a history of treatment

Figure 1 Strategy for treatment of HCC employed at our institution. Nearly all patients with HCC, which were outside of the Milan criteria, were recommended for a repeated TAE course.

Figure 2 Survival rates of HCC patients with or without past treatment for HCC. There was no significant difference between the 2 groups. Survival rates after 1, 2, and 3 years were 90%, 57%, and 20% respectively for patients without past treatment, and 75%, 43%, and 25% respectively for patients with past treatment.

Figure 3 Survival rates of HCC patients with past treatment and with or without the 2 risk factors found in the present study. Significant differences were shown between “a” and “b” and between “b” and “c” (P < 0.01 and P = 0.01), while there were no significant differences between “a” and “b” (P = 0.08). a: Patients without either factor [existence of bilobular tumors and high concentration of AFP (greater than 100 ng/mL; n = 16)]; b: Patients with one of the factors (n = 47); c: Patients with both factors (n = 21).